Nonabsorbable nasal packing is often placed for the treatment of epistaxis or after sinonasal or skull base surgery. Antibiotics are often prescribed to prevent toxic shock syndrome (TSS), a rare, potentially fatal occurrence. However, the risk of TSS must be balanced against the major risk of antibiotic use, specifically Clostridium difficile colitis (CDC). The purpose of this study is to evaluate in terms of cost-effectiveness whether antibiotics should be prescribed when nasal packing is placed.
Study Design
A clinical decision analysis was performed using a Markov model to evaluate whether antibiotics should be given.
Setting
Patients with nonabsorbable nasal packing placed.
Methods
Utility scores, probabilities, and costs were obtained from the literature. We assess the cost-effectiveness of antibiotic use when the risk of community-acquired CDC is balanced against the risk of TSS from nasal packing. Sensitivity analysis was performed for assumptions used in the model.
Results
The incremental cost-effectiveness ratio for antibiotic use was 334,493 US dollars (USD)/quality-adjusted life year (QALY). Probabilistic sensitivity analysis showed that not prescribing antibiotics was cost-effective in 98.0% of iterations at a willingness to pay of 50,000 USD/QALY. Sensitivity analysis showed that when the risk of CDC from antibiotics was greater than 910/100,000 or when the incidence of TSS after nasal packing was less than 49/100,000 cases, the decision to withhold antibiotics was cost-effective.
Conclusions
Routine antibiotic prophylaxis in the setting of nasal packing is not cost-effective and should be reconsidered. Even if antibiotics are assumed to prevent TSS, the risk of complications from antibiotic use is of greater consequence.
LangeJLPeedenEHStringerSP.Are prophylactic systemic antibiotics necessary with nasal packing? A systematic review. Am J Rhinol Allergy. 2017;31(4):240-247.
2.
WannemuehlerTJRabbaniCCBurgesonJE, et al. Survey of endoscopic skull base surgery practice patterns among otolaryngologists. Laryngoscope Investig Otolaryngol. 2018;3(3):143-155.
3.
VillwockJAJonesK.Recent trends in epistaxis management in the United States: 2008-2010. JAMA Otolaryngol Head Neck Surg. 2013;139(12):1279-1284.
4.
ShargorodskyJBleierBSHolbrookEH, et al. Outcomes analysis in epistaxis management: development of a therapeutic algorithm. Otolaryngol Head Neck Surg. 2013;149(3):390-398.
5.
MuranoTBrucato-DuncanDRamdinCKellerS.Prophylactic systemic antibiotics for anterior epistaxis treated with nasal packing in the ED. Am J Emerg Med. 2019;37(4):726-729.
6.
JacobsonJAKaswormEM.Toxic shock syndrome after nasal surgery. Case reports and analysis of risk factors. Arch Otolaryngol Head Neck Surg. 1986;112(3):329-332.
7.
ThomasSWBairdIMFrazierRD.Toxic shock syndrome following submucous resection and rhinoplasty. JAMA. 1982;247(17):2402-2403.
8.
TobackJFayermanJW.Toxic shock syndrome following septorhinoplasty: implications for the head and neck surgeon. Arch Otolaryngol. 1983;109(9):627-629.
9.
HullHFMannJMSandsCJGreggSHKaufmanPW.Toxic shock syndrome related to nasal packing. Arch Otolaryngol. 1983;109(9):624-626.
10.
BarbourSDShlaesDMGuertinSR.Toxic-shock syndrome associated with nasal packing: analogy to tampon-associated illness. Pediatrics. 1984;73(2):163-165.
11.
AeumjaturapatSSupanakornSCutchavareeA.Toxic shock syndrome after anterior-posterior nasal packing. J Med Assoc Thai. 2001;84(3):453-458.
12.
SuzukiSYasunagaHMatsuiHFushimiKKondoKYamasobaT.Complication rates after functional endoscopic sinus surgery: analysis of 50,734 Japanese patients. Laryngoscope. 2015;125(8):1785-1791.
GaensbauerJTBirkholzMSmitMAGarciaRToddJK.Epidemiology and clinical relevance of toxic shock syndrome in US children. Pediatr Infect Dis J. 2018;37(12):1223-1226.
15.
HajjehRAReingoldAWeilAShuttKSchuchatAPerkinsBA.Toxic shock syndrome in the United States: surveillance update, 1979-1996. Emerg Infect Dis. 1999;5(6):807-810.
16.
DeVriesASLesherLSchlievertPM, et al. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS One. 2011;6(8):e22997.
17.
BiggsTCNightingaleKPatelNNSalibRJ.Should prophylactic antibiotics be used routinely in epistaxis patients with nasal packs?Ann R Coll Surg Engl. 2013;95(1):40-42.
18.
BiswasDMalRK.Are systemic prophylactic antibiotics indicated with anterior nasal packing for spontaneous epistaxis?Acta Otolaryngol. 2009;129(2):179-181.
19.
PepperCLoSTomaA.Prospective study of the risk of not using prophylactic antibiotics in nasal packing for epistaxis. J Laryngol Otol. 2012;126(3):257-259.
20.
TranQKRehanMAHaaseDJMattaAPourmandA.Prophylactic antibiotics for anterior nasal packing in emergency department: a systematic review and meta-analysis of clinically-significant infections. Am J Emerg Med. 2020;38(5):983-989.
21.
RudmikLSmithTL.Management of intractable spontaneous epistaxis. Am J Rhinol Allergy. 2012;26(1):55-60.
22.
BarnesMLSpielmannPMWhitePS.Epistaxis: a contemporary evidence based approach. Otolaryngol Clin North Am. 2012;45(5):1005-1017.
23.
BiswasDWilsonHMalR.Use of systemic prophylactic antibiotics with anterior nasal packing in England, UK. Clin Otolaryngol. 2006;31(6):566-567.
24.
CohnB.Are prophylactic antibiotics necessary for anterior nasal packing in epistaxis?Ann Emerg Med. 2015;65(1):109-111.
25.
DubberkeEROlsenMA.Burden of Clostridium difficile on the healthcare system. Clin Infect Dis. 2012;55(suppl 2):S88-S92.
26.
BeaugerieLFlahaultABarbutF, et al. Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther. 2003;17(7):905-912.
27.
HirschhornLRTrnkaYOnderdonkALeeMLPlattR.Epidemiology of community-acquired Clostridium difficile–associated diarrhea. J Infect Dis. 1994;169(1):127-133.
28.
KoehlerPJungNKochanekMLohneisPShimabukuro-VornhagenABollB.‘Lost in nasal space’: Staphylococcus aureus sepsis associated with nasal handkerchief packing. Infection. 2019;47(2):307-311.
29.
KyneLWarnyMQamarAKellyCP.Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342(6):390-397.
30.
StromMAHsuDYSilverbergJI.Prevalence, comorbidities and mortality of toxic shock syndrome in children and adults in the USA. Microbiol Immunol. 2017;61(11):463-473.
LamagniTLNealSKeshishianC, et al. Predictors of death after severe Streptococcus pyogenes infection. Emerg Infect Dis. 2009;15(8):1304-1307.
33.
ParksTWilsonCCurtisNNorrby-TeglundASriskandanS.Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis. 2018;67(9):1434-1436.
34.
YendeSAustinSRhodesA, et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med. 2016;44(8):1461-1467.
35.
KuntzJLChrischillesEAPendergastJFHerwaldtLAPolgreenPM.Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis. 2011;11:194.
36.
KhannaSPardiDSAronsonSL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107(1):89-95.
37.
ByrnJCMaunDCGingoldDSBarilDTOzaoJJDivinoCM.Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143(2):150-155.
38.
ManekKWilliamsVCallerySDanemanN.Reducing the risk of severe complications among patients with Clostridium difficile infection. Can J Gastroenterol. 2011;25(7):368-372.
39.
SailhamerEACarsonKChangY, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144(5):433-440.
40.
DowdyDWEidMPSedrakyanA, et al. Quality of life in adult survivors of critical illness: a systematic review of the literature. Intensive Care Med. 2005;31(5):611-620.
41.
SuYXXuLGaoXJWangZYLuXYinCF.Long-term quality of life after sepsis and predictors of quality of life in survivors with sepsis. Chin J Traumatol. 2018;21(4):216-223.
42.
HofhuisJGSpronkPEvan StelHFSchrijversAJRommesJHBakkerJ.The impact of severe sepsis on health-related quality of life: a long-term follow-up study. Anesth Analg. 2008;107(6):1957-1964.
43.
KonijetiGGSaukJShrimeMGGuptaMAnanthakrishnanAN.Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis. 2014;58(11):1507-1514.
44.
MuirAJEdwardsLJSandersLL, et al. A prospective evaluation of health-related quality of life after ileal pouch anal anastomosis for ulcerative colitis. Am J Gastroenterol. 2001;96(5):1480-1485.
45.
ZhangSPalazuelos-MunozSBalsellsEMNairHChitAKyawMH.Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study. BMC Infect Dis. 2016;16(1):447.
46.
VarierRUBiltajiESmithKJ, et al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect. 2014;20(12):1343-1351.
